The latest news in Fibrous Dysplasia/McCune-Albright Syndrome
IMPORTANT FUNDING ALERT FOR FIBROUS DYSPLASIA RESEARCH
The US Department of Defense has just released a funding announcement for the Peer Reviewed Medical Research Program. Fibrous dysplasia was recently named as one of the disease topic areas eligible for funding through the Peer-Reviewed Medical Research Program (PRMRP).Our goal is that FD/MAS researchers are awarded some of the $360 million dollars allocated to the PRMRP, and we hope that many of you will apply.
Please share this email with any of your colleagues who may be interested in submitting a research proposal that addresses aspects of fibrous dysplasia/McCune-Albright Syndrome (FD/MAS) and helps support the PRMRP goal of enhancing the health and well-being of military service members, veterans, and their families.
The mutation that causes FD/MAS is located in a very important gene (GNAS) that is necessary for the maintenance of healthy bone. For that reason, the study of FD/MAS has a track record of yielding broad insights about bone biology, including the discovery that bone is the body's source of a key kidney-regulating hormone, FGF23. FD/MAS provides a unique natural experiment to study key signaling pathways that have implications for treatments of conditions important to the DOD, including blast-induced heterotopic ossification, chronic bone pain, skeletal fractures, osteoporosis, and osteoarthritis.
